Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia
Barnett PG, Scott JY, Krystal JH, Rosenheck RA
 
 
Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.
Bibliographic details
Barnett PG, Scott JY, Krystal JH, Rosenheck RA. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. Journal of Clinical Psychiatry 2012; 73(5): 696-702
PubMedID
22697193
DOI
10.4088/JCP.11m07070
Original Paper URL
http://article.psychiatrist.com/dao_ 1-login.asp?ID=10007874& amp;RSID=54764774725668
Indexing Status
Subject indexing assigned by NLM
MeSH
Antipsychotic Agents /economics /therapeutic use; Comparative Effectiveness Research; Cost-Benefit Analysis; Delayed-Action Preparations; Double-Blind Method; Drug Costs; Female; Health Care Costs; Hospitalization /economics /statistics & Humans; Injections; Kaplan-Meier Estimate; Male; Middle Aged; Models, Econometric; Psychotic Disorders /drug therapy; Risperidone /economics /therapeutic use; Schizophrenia /drug therapy; United States; Veterans; numerical data
AccessionNumber
22012024012
Date bibliographic record published
08/01/2013
 
NHS Economic Evaluation Database (NHS EED)
Produced by the Centre for Reviews and Dissemination
Copyright © 2025 University of York
 
Homepage
Options
Print
PDF
 
PubMed record
Original research
 
Share
 

Message for NHS EED database users